DETECTION AND ANTIMICROBIAL SUSCEPTIBILITY PATTERN OF PSEUDOMONAS AERUGINOSA ISOLATES IN VARIOUS CLINICAL SAMPLES WITH SPECIAL REFERENCE TO METALLO BETA LACTAMASE FROM A TERTIARY CARE HOSPITAL IN JAIPUR, INDIARakesh Kumar, Preeti Srivastava, Suman rishi, Sharmendra singh dahiya, Kirti Hemwani, Prem singh Nirwan.
Introduction- Pseudomonas aeruginosa is a classic opportunistic pathogen because of its innate resistance to many antibiotics and disinfectants. In recent years, considerable increase in the prevalence and multidrug resistance (MDR) in P.aeruginosa has been noticed with high morbidity and mortality. The wide spread dissemination of Metallo Beta Lactamase (MBL) production has led to resistance to antibiotics like carbapenems, such as Imipenem and Meropenem, among gram negative pathogens including Pseudomonas aeruginosa have become a global concern. Aim of the present study was to determine the status of antimicrobial susceptibility to anti Pseudomonal agents and to detect Metallo Beta lactamase.
Material and Methods- This study was conducted from August 2012 to September 2013. During this period 100 isolates of Pseudomonas aeruginosa were isolate. The organisms were identified on the basis of their cultural characteristics and biochemical tests. Antimicrobial susceptibility of all the isolates was performed by the Kirby- bauer disc-diffusion method according to CLSI guidelines. MBL producing P. aeruginosa were detected by phenotypic method IPM-EDTA combined disc synergy test.
Results- In present study P. aeruginosa were most sensitive to Colistin followed by Polymyxin- B, Piperacilli/Tazobactam, Cefoperazone/Sulbactam, Imipenem, Meropenem, Ciprofloxacin, Amikacin, Gentamycin, Ceftazidime, Tobramycin and Aztreonam. 32 isolates were imipenem resistant and out of 32 isolates, 20 were MBL producers detected by IPM-EDTA combined disc synergy test.
Conclusions- Colistin and Polymyxin-B are more effective to treat multidrug resistant P.aeruginosa. The early detection of MBL producing P. aeruginosa may help in appropriate anti-Pseudomonal therapy to stop the development & dissemination of multidrug resistance strains.
Antimicrobial Susceptibility, Pseudomonas aeruginosa, Metallo Beta Lactamase, Combined Disc Synergy Test, Multidrug resistant.